Page last updated: 2024-09-05

muraglitazar and Dyslipidemia

muraglitazar has been researched along with Dyslipidemia in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cap, M; Chang, C; Cheng, PT; Chu, C; Devasthale, P; Doweyko, AM; Farrelly, D; Gu, L; Hariharan, N; Harrity, T; Hosagrahara, V; Kadiyala, P; Kunselman, L; Lippy, J; Locke, K; Morgan, N; Muckelbauer, J; O'Malley, K; Ponticiello, R; Ryono, D; Wang, W; Zahler, R; Zebo, R; Zhang, L1
Cox, SL1

Reviews

1 review(s) available for muraglitazar and Dyslipidemia

ArticleYear
Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia.
    Drugs of today (Barcelona, Spain : 1998), 2005, Volume: 41, Issue:9

    Topics: Adult; Aged; Animals; Area Under Curve; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Glycated Hemoglobin; Glycine; Half-Life; Humans; Hypoglycemic Agents; Male; Oxazoles; Peroxisome Proliferator-Activated Receptors; Tissue Distribution

2005

Other Studies

1 other study(ies) available for muraglitazar and Dyslipidemia

ArticleYear
Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.
    Bioorganic & medicinal chemistry letters, 2008, Mar-15, Volume: 18, Issue:6

    Topics: Administration, Oral; Animals; Azetidines; Biological Availability; Copper; Crystallography, X-Ray; Cytochrome P-450 Enzyme Inhibitors; Diabetes Mellitus, Experimental; Dyslipidemias; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Glucose; Mice; Mice, Mutant Strains; Molecular Structure; PPAR alpha; PPAR gamma; Protein Conformation; Stereoisomerism; Structure-Activity Relationship; Triglycerides

2008